BRPI0515383A - n-etil hidroxietilamina útil no tratamento de condições do snc - Google Patents

n-etil hidroxietilamina útil no tratamento de condições do snc

Info

Publication number
BRPI0515383A
BRPI0515383A BRPI0515383-2A BRPI0515383A BRPI0515383A BR PI0515383 A BRPI0515383 A BR PI0515383A BR PI0515383 A BRPI0515383 A BR PI0515383A BR PI0515383 A BRPI0515383 A BR PI0515383A
Authority
BR
Brazil
Prior art keywords
useful
conditions
treating
snc
ethyl hydroxyethylamine
Prior art date
Application number
BRPI0515383-2A
Other languages
English (en)
Inventor
Edward Fox Kleinman
John Charles Murray
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0515383A publication Critical patent/BRPI0515383A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

N-ETIL HIDROXIETILAMINA úTIL NO TRATAMENTO DE CONDIçõES DO SNC. é revelada uma N-etil hidroxietilamina útil no tratamento de condições do SNC, incluindo condições neurodegenerativas, tais como doença de Alzheimer.
BRPI0515383-2A 2004-09-21 2005-09-09 n-etil hidroxietilamina útil no tratamento de condições do snc BRPI0515383A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61168504P 2004-09-21 2004-09-21
PCT/IB2005/002878 WO2006033000A2 (en) 2004-09-21 2005-09-09 N-ethyl hydroxyethylamine useful in treating cns conditions

Publications (1)

Publication Number Publication Date
BRPI0515383A true BRPI0515383A (pt) 2008-07-22

Family

ID=35708665

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515383-2A BRPI0515383A (pt) 2004-09-21 2005-09-09 n-etil hidroxietilamina útil no tratamento de condições do snc

Country Status (7)

Country Link
US (1) US20070213368A1 (pt)
EP (1) EP1794115A2 (pt)
JP (1) JP2008513433A (pt)
BR (1) BRPI0515383A (pt)
CA (1) CA2580775A1 (pt)
MX (1) MX2007003281A (pt)
WO (1) WO2006033000A2 (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2410680A1 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
AU2002320490B2 (en) * 2001-07-11 2008-10-02 Elan Pharmaceuticals, Inc. N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds
HRP20040857A2 (en) * 2002-02-27 2005-06-30 Pharmacia & Upjohn Company Elan Pharmaceuticals Substituted hydroxyethylamines
GB0228410D0 (en) * 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
GB0309221D0 (en) * 2003-04-23 2003-06-04 Glaxo Group Ltd Novel compounds
GB0328900D0 (en) * 2003-12-12 2004-01-14 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
WO2006033000A3 (en) 2006-05-18
JP2008513433A (ja) 2008-05-01
US20070213368A1 (en) 2007-09-13
EP1794115A2 (en) 2007-06-13
MX2007003281A (es) 2007-05-18
WO2006033000A2 (en) 2006-03-30
CA2580775A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
BRPI0515528A (pt) n-metil hidroxietilamina úteis no tratamento de condições do sistema nervoso central
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
DE59914996D1 (en) Heterocyclisch substituierte amide als calpainhemmer
SE0203713D0 (sv) Novel compounds
ZA200709535B (en) Methods and compositions for the treatment of CNS-related conditions
BRPI0414598A (pt) indóis substituìdos
ECSP066355A (es) Compuestos de 2-(quinoxalin-5-ilsulfonilamino)-benzamida como moduladores de la colecistocinina 2
DK1560812T3 (da) Aminocyclohexyletherforbindelser og anvendelser deraf
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
BRPI0515371A (pt) hidantoìnas substituìdas
ATE415968T1 (de) 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen
BRPI0514515A (pt) hidantoìnas substituìdas
WO2005044200A3 (en) Methods and compositions for treating mcp-1 related pathologies
NO20055741L (no) Nye kjemiske forbindelser
TW200744567A (en) Phenylethylamine analogs and their use for treating glaucoma
ATE552251T1 (de) Thiophen- und furanverbindungen
TW200716088A (en) Formulations and methods for treating amyloidosis
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
ATE410166T1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate zur behandlung von unfruchtbarkeit
DE602004026597D1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
TW200738143A (en) Use of arylanilides for seed treatment

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.